Novartis: Diabetes Mellitus trials
The registry lists 37 Diabetes Mellitus studies with Novartis as lead sponsor. 0 are open to participants now and 13 have results posted.
Phase 1 3Phase 2 10Phase 3 8Phase 4 16No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic NephropathyCompletedNCT03804879Phase 2Results posted
- Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic SyndromeCompletedNCT03440736Phase 4Results posted
- A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart FailureTerminatedNCT03152552Phase 2Results posted
- Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.CompletedNCT02670928Phase 4Results posted
- Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)CompletedNCT02597127Phase 2Results posted
- A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) PatientsCompletedNCT02259088Phase 3Results posted
- Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment PhaseTerminatedNCT02032173Phase 3Results posted
- Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and GlimepirideCompletedNCT02007278Phase 4Results posted
- Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM PatientsCompletedNCT02002221Phase 4Results posted
- Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and DiabetesTerminatedNCT01368536Phase 4Results posted
- Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)CompletedNCT01135914Phase 3Results posted
- Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes MellitusCompletedNCT00787605Phase 4Results posted
- Efficacy of Aliskiren in the Treatment of Diabetic Macular EdemaTerminatedNCT00768040Phase 2Results posted
- Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United StatesCompletedNCT07214857
- Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKiaCompletedNCT02232503
- Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II DiabetesTerminatedNCT01862263Phase 4
- Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763CompletedNCT01619332Phase 1/2
- Real-world Aliskiren Use in Diabetic PatientsCompletedNCT01393860
- Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 DiabetesCompletedNCT01357252Phase 3
- Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 DiabetesCompletedNCT01356381Phase 4
- ACZ885 in Type 1 Diabetes MellitusWithdrawnNCT01322321Phase 2
- Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial TreatmentCompletedNCT01257815Phase 4
- Phase 4 Study in the Elderly Patients With T2DMCompletedNCT01238978Phase 4
- Glycemic Holter Study (Continuous Glucose Monitoring) -CompletedNCT01193296Phase 4
- Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin MonotherapyCompletedNCT00822211Phase 3
- Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired PatientsCompletedNCT00818571Phase 1/2
- Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy SubjectsCompletedNCT00651105Phase 3
- Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 DiabetesTerminatedNCT00633997Phase 1/2
- Effect of Tegaserod on Gastric Emptying in Patients With Diabetic GastroparesisTerminatedNCT00390975Phase 4
- Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes MellitusCompletedNCT00367978Phase 4
- A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder PatientsCompletedNCT00219102Phase 3
- A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.CompletedNCT00219089Phase 3
- Conversion From Tacrolimus to Cyclosporine Microemulsion in Liver Transplant Patients With New Onset Diabetes After the 3rd Month Post-transplantCompletedNCT00171717Phase 4
- Valsartan/Hydrochlorothiazide Combination vs Amlodipine in Patients With Hypertension, Diabetes, and Albuminuria.CompletedNCT00171561Phase 4
- Safety and Efficacy of Converting Maintenance Kidney and Liver Transplant Recipients With Abnormal Glucose Metabolism From Tacrolimus to Cyclosporine Micro-emulsionTerminatedNCT00150085Phase 4
- Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic GastropathyTerminatedNCT00142974Phase 2
- Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and ProteinuriaCompletedNCT00097955Phase 2